Results - measured by the alkaline hematin method - found that at 6 months those in the combination group had 76.2% (P<0.001) clinical response compared to the elagloix along group, in which only 10.1% had a clinical response.
Ulipristal acetate is a selective progesterone receptor modulator which acts directly on the progesterone receptors in the endometrium, uterine fibroids, and the pituitary gland.
Data from a large, 1-year postmarketing safety study conducted in Europe found that lactation at the time of insertion of an IUD/IUS was associated with an increased risk of perforation.
Amerigen announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Tranexamic Acid Instant Release Tablets, the generic version of Ferring's Lysteda.
Adolescent girls undergoing treatment for cancer are at high risk for heavy menstrual bleeding, and gynecologic care is advised for careful management of this problem.
Treatment of heavy menstrual bleeding is associated with improvements in health-related quality of life, with greater improvements for women with anemia at baseline.
For Chinese women, the age of menarche and menopause is not related to the risk of diabetes, but does correlate with cardiovascular disease and osteoporosis.
Intake of specific minerals seem to be associated with the risk of premenstrual syndrome (PMS), with high intake of nonheme iron linked to reduced risk of PMS.
Compared with standard medical therapy, women with menorrhagia experience more effective, sustained physical and quality-of-life benefits from treatment with a levonorgestrel-releasing intrauterine system (IUS).
Watson announced that it has received FDA approval on its Abbreviated New Drug Application for Tranexamic Acid Tablets, the generic version of Ferring's Lysteda.